Trupanion Inc (NASDAQ:TRUP) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 5,243,952 shares, a growth of 30.5% from the February 15th total of 4,019,568 shares. Based on an average daily trading volume, of 364,345 shares, the short-interest ratio is presently 14.4 days. Approximately 37.4% of the company’s shares are sold short.
Several equities research analysts have weighed in on the stock. ValuEngine cut shares of Trupanion from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. BidaskClub raised shares of Trupanion from a “sell” rating to a “hold” rating in a research report on Saturday, March 3rd. Zacks Investment Research cut shares of Trupanion from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. Lake Street Capital increased their price target on shares of Trupanion from $32.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Finally, Cowen reissued an “outperform” rating and set a $38.00 price target (up previously from $32.00) on shares of Trupanion in a research report on Wednesday, February 14th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $35.57.
Shares of Trupanion (TRUP) opened at $36.54 on Tuesday. Trupanion has a 12-month low of $13.88 and a 12-month high of $36.88. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.89 and a quick ratio of 1.89. The company has a market cap of $1,078.59, a PE ratio of -608.90 and a beta of 0.57.
In other Trupanion news, Director Murray B. Low sold 3,000 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $28.42, for a total transaction of $85,260.00. Following the completion of the sale, the director now owns 194,281 shares of the company’s stock, valued at approximately $5,521,466.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Darryl Rawlings sold 3,500 shares of the stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $30.11, for a total transaction of $105,385.00. Following the sale, the insider now directly owns 1,389,976 shares of the company’s stock, valued at approximately $41,852,177.36. The disclosure for this sale can be found here. Insiders have sold a total of 24,000 shares of company stock valued at $746,760 in the last three months. 31.24% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the company. First Mercantile Trust Co. purchased a new stake in shares of Trupanion in the 4th quarter worth about $129,000. JPMorgan Chase & Co. purchased a new stake in shares of Trupanion in the 3rd quarter worth about $143,000. Advisor Group Inc. purchased a new stake in shares of Trupanion in the 4th quarter worth about $182,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Trupanion in the 3rd quarter worth about $221,000. Finally, Voya Investment Management LLC purchased a new stake in shares of Trupanion in the 2nd quarter worth about $215,000. 74.75% of the stock is owned by hedge funds and other institutional investors.
Trupanion, Inc provides medical insurance plans for cats and dogs throughout the United States, Canada and Puerto Rico. The Company operates in two business segments: subscription business and other business. The subscription business segment includes monthly subscriptions for its medical plan, which are marketed to consumers.
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.